- Category
- Client Alerts
- Date
- Dec. 19, 2014
- Title
-
Federal Circuit Rules Myriad’s ‘Primers’ and Methods Are Not Patent-Eligible Subject Matter
This client alert examines the U.S. Court of Appeals for the Federal Circuit’s December 17, 2014 decision regarding patent eligibility of DNA-based inventions in the case In re BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation. The alert will summarize and analyze the Court’s decision in the context of other decisions concerning patents of genetic material.
Media Attachments
Related People
-
-
Christine Willgoos
-
- Special Counsel
- Co-author
- New York
- vcard
-
